Aduhelm’s loss is a win for value-based drug pricing August 10, 2022 AutoBot Aduhelm, alzheimer's disease, Biogen, BioPharma, biopharma nl, drug pricing, MedCity Influencers, Opinion 0 Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based contracts are the only way to figure that out.